Greenpeace to step up fight against GM canola in Australia
08 January, 2003 by Graeme O'NeillGreenpeace Australia Pacific has signalled that it will step up its campaign to block the introduction of genetically modified canola into Australia, by advertising for a new anti-GM campaigner.
Scale-up problems force layoffs at Ambri
08 January, 2003 by Pete YoungListed biotech Ambri Ltd has laid off 15 staff in response to unexpected manufacturing problems in scaling up its biosensor technology for commercial production.
Research points the whey forward for milk
20 December, 2002 by Graeme O'NeillMilk is the first food that any mammal tastes, a fluid perfectly formulated by nature for the nutritional and developmental needs of newborn mammals.
Biotech's six million dollar woman
20 December, 2002 by Pete YoungA young biotech that is developing technology to improve racehorse performance is easily outpacing the field when it comes to attracting development funding.
ESI gets rights to diabetes technology
19 December, 2002 by Melissa TrudingerSingapore-based stem cell company ES Cell International (ESI) has acquired patent rights to technology relating to the transformation of stem cells into insulin-producing cells from US company Curis.
Local biotechs unhappy with ASIC report
19 December, 2002 by Pete YoungA number of listed biotechs named by the Australian Securities and Investments Commission (ASIC) as facing potential solvency problems are crying foul.
US maize shipments tipped to to raise anti-GM hackles
18 December, 2002 by Graeme O'NeillAs a desperate measure to keep alive elite dairy and beef cattle herds suffering in one of the worst droughts of the past century, Australia's livestock industries are moving to ship in maize from the US.
Genetraks raises $6m
18 December, 2002 by Pete YoungGenetraks, a start-up biotech developing blood tests for use in pre-race evaluation of animals such as racehorses, has received a $6 million injection of venture capital.
INTERVIEW: The Andrews view: hang on for a big 2003
17 December, 2002 by Pete YoungThe biotech shake-up will intensify in 2003 but the horizon looks inviting on the far side of the wave of mergers expected to roll through the sector over the next 12 to 24 months. That's the view of Prof Peter Andrews, a leading member of the generation which has dramatically reshaped Australian bioscience in the last 15 years and a man who boasts a good track record in sculpting positive environments for young biotechs.
Cochlear scholarship to encourage would-be tertiary students
16 December, 2002 by Melissa TrudingerBionic ear company Cochlear has set up a scholarship to encourage recipients of its cochlear implants to go on to tertiary education.
Xenome in new UK partnership
13 December, 2002 by Pete YoungDrug developer Xenome is adding UK biotech TheraSci to the list of partner firms screening Xenome's venom-based peptide molecules against validated drug targets.
Cytopia close to selecting first drug lead compound
13 December, 2002 by Melissa TrudingerMelbourne drug discovery company Cytopia is close to selecting its first drug lead compound for the treatment of hormone refractory prostate cancer, after getting encouraging results from pre-clinical animal studies.
Virax opens new manufacturing unit
13 December, 2002 by Melissa TrudingerVirax Holdings has opened a new Vector Construction Unit (VCU) located in the School of Biomedical Sciences at Monash University.
Proteome Systems makes a sweet deal with Nestle
12 December, 2002 by Pete YoungSydney-based Proteome Systems has sweetened its chances of cashing in on its expertise in the promising field of sugar-coated proteins by signing a research pact with the world's leading food company, Nestle.
Eiffel cashed-up for 2003
12 December, 2002 by Melissa TrudingerEiffel Technologies has increased its cash reserves to $6.2 million following receipt of partial payment from the sale of their manufacturing operation to Cottee International and a recent share placement.
